Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Aggression × Ifosfamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 70 Lymphoma 50 Lymphoma, Large B-Cell, Diffuse 47 Lymphoma, Non-Hodgkin 28 Osteosarcoma 27 Precursor Cell Lymphoblastic Leukemia-Lymphoma 24 Hodgkin Disease 24 Burkitt Lymphoma 19 Testicular Neoplasms 17 Leukemia 17 Ovarian Neoplasms 16 Lymphoma, Follicular 16 Neuroectodermal Tumors, Primitive, Peripheral 15 Lymphoma, Large-Cell, Immunoblastic 13 Fibrosarcoma 12 Rhabdomyosarcoma 11 Lymphoma, Mantle-Cell 11 Testicular Germ Cell Tumor 10 Teratoma 10 Recurrence 10 Neurofibrosarcoma 10 Lymphoma, B-Cell, Marginal Zone 10 Liposarcoma 10 Leukemia, Lymphocytic, Chronic, B-Cell 10 Leiomyosarcoma 10 Sarcoma, Synovial 9 Neoplasms 9 Lymphoma, Large-Cell, Anaplastic 9 Histiocytoma, Malignant Fibrous 9 Hemangiosarcoma 9

Interventions

vandetanib 1 selinexor 1 pegfilgrastim 1 midostaurin 1 glofitamab 1 Topotecan 1 Rituximab 1 Prednisone 1 Positron Emission Tomography Computed Tomography 1 Paclitaxel 1 Methylprednisolone 1 Immunologic Techniques 1 Ifosfamide 1 Flow Cytometry 1 Etoposide 1 Dexamethasone 1 Carboplatin 1 Alemtuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02471911 2022-04-12

KPT-330+RICE

Weill Medical College of Cornell University

Phase 1 Completed

Aggression, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡